European Union - English - EMA (European Medicines Agency)

sandoz pharmaceuticals d.d. - nelarabine - precursor t-cell lymphoblastic leukemia-lymphoma - antineoplastic agents - nelarabine is indicated for the treatment of patients with t-cell acute lymphoblastic leukaemia (t-all) and t-cell lymphoblastic lymphoma (t-lbl) whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. due to the small patient populations in these disease settings, the information to support these indications is based on limited data.,

European Union - English - EMA (European Medicines Agency)

sandoz pharmaceuticals d.d. - topotecan - ovarian neoplasms; uterine cervical neoplasms; small cell lung carcinoma - antineoplastic agents - hycamtin capsules are indicated as monotherapy for the treatment of adult patients with relapsed small cell lung cancer (sclc) for whom re-treatment with the first-line regimen is not considered appropriate.topotecan is indicated for the treatment of patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy.hycamtin capsules are indicated as monotherapy for the treatment of adult patients with relapsed small cell lung cancer (sclc) for whom re-treatment with the first-line regimen is not considered appropriate.

European Union - English - EMA (European Medicines Agency)

sandoz gmbh - ibandronic acid - breast neoplasms; neoplasm metastasis; fractures, bone - drugs for treatment of bone diseases, bisphosphonates - ibandronic acid sandoz is indicated for the prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.,

European Union - English - EMA (European Medicines Agency)

1 a pharma gmbh - rivastigmine - alzheimer disease; dementia; parkinson disease - psychoanaleptics, - symptomatic treatment of mild to moderately severe alzheimer's dementia.symptomatic treatment of mild to moderately severe dementia in patients with idiopathic parkinson's disease.

European Union - English - EMA (European Medicines Agency)

hexal ag  - rivastigmine - dementia; alzheimer disease; parkinson disease - psychoanaleptics, - symptomatic treatment of mild to moderately severe alzheimer's dementia.symptomatic treatment of mild to moderately severe dementia in patients with idiopathic parkinson's disease.

European Union - English - EMA (European Medicines Agency)

sandoz gmbh - rivastigmine - dementia; alzheimer disease; parkinson disease - psychoanaleptics, - symptomatic treatment of mild to moderately severe alzheimer's dementia.symptomatic treatment of mild to moderately severe dementia in patients with idiopathic parkinson's disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - dobutamine hydrochloride 14.01 mg/ml equivalent to dobutamine 12.5 mg/ml - concentrate for injection - 12.5 mg/ml - active: dobutamine hydrochloride 14.01 mg/ml equivalent to dobutamine 12.5 mg/ml excipient: hydrochloric acid nitrogen sodium hydroxide sodium metabisulfite water for injection - dobutamine hydrochloride is indicated when inotropic support is necessary for the treatment of patients with hypoperfusion states in whom cardiac output is insufficient to meet circulatory demands. dobutamine hydrochloride is also indicated when inotropic support is required for the treatment of patients in whom abnormally increased ventricular filling pressures introduce the risk of pulmonary congestion and oedema. conditions which may precipitate such situations include the following hypoperfusion states: initially cardiac in origin a. acute heart failure 1. acute myocardial infarction 2. cardiogenic shock 3. following cardiac surgery 4. medicine-induced depression of cardiac contractility such as that which occurs in excessive ?- adrenergic receptor blockade. b. chronic heart failure 1. acute decompensation of chronic congestive heart failure 2. temporary inotropic support in advanced chronic congestive heart failure, as an adjunct to therapy with conventional oral inotropic agents, systemic vasodilators, and diuretics. initially noncardiac in origin 1. acute hypoperfusion states secondary to trauma, surgery, sepsis, or hypovolaemia when mean arterial pressure is above 70-mm hg and pulmonary capillary wedge pressure is 18-mm hg or greater, with inadequate response to volume repletion and increased ventricular filling pressure 2. low cardiac output secondary to mechanical ventilation with positive end-expiratory pressure (peep). paediatric population dobutamine is indicated in all paediatric age groups (from neonates to 18 years of age) as inotropic support in low cardiac output hypoperfusion states resulting from decompensated heart failure, following cardiac surgery, cardiomyopathies and in cardiogenic or septic shock.

Canada - English - Health Canada

pfizer canada ulc - propofol - emulsion - 10mg - propofol 10mg - miscellaneous general anesthetics

Canada - English - Health Canada

pfizer canada ulc - propofol - emulsion - 10mg - propofol 10mg - miscellaneous general anesthetics

Canada - English - Health Canada

baxter corporation - propofol - emulsion - 10mg - propofol 10mg - miscellaneous general anesthetics